Title: A repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological and biological age-dependent changes.

Authors: Felix Stader\textsuperscript{1,2,3,5}, Marco Siccardi\textsuperscript{4}, Manuel Battegay\textsuperscript{1,3}, Hannah Kinvig\textsuperscript{4}, Melissa A. Penny\textsuperscript{2,3} & Catia Marzolini\textsuperscript{1,3}

Affiliation: 1. Division of Infectious Diseases and Hospital Epidemiology
Departments of Medicine and Clinical Research
University Hospital Basel
Basel, Switzerland

2. Infectious Disease Modelling Unit
Department of Epidemiology and Public Health
Swiss Tropical and Public Health Institute
Basel, Switzerland

3. University of Basel
Basel, Switzerland

4. Department of Molecular and Clinical Pharmacology
Institute of Translational Medicine
University of Liverpool
Liverpool, UK

$ \text{corresponding author}$
E-mail: Felix.Stader@unibas.ch
Phone: +41 61 284 8738

Keywords: Aging, elderly, PBPK, modelling, population database

Article Type: Original Research Article
1 Abstract

Background
Aging is characterized by anatomical, physiological and biological changes which can impact drug kinetics. Elderly are often excluded from clinical trials and knowledge about drug kinetics and drug-drug interaction (DDI) magnitudes are sparse. Physiologically based pharmacokinetic (PBPK) modelling can overcome this clinical limitation but detailed descriptions of the population characteristics are essential to adequately inform models.

Objective
The objective of this work was to develop and verify a population database for aging Caucasians considering anatomical, physiological and biological system parameters required to inform a PBPK model with included population variability.

Methods
A structured literature search was performed to analyze age-dependent changes of system parameters. All collated data were carefully analyzed, and descriptive, mathematical equations were derived.

Results
A total of 362 studies were found of which 318 studies were included in the analysis as they reported rich data for anthropometric parameters and specific organs (e.g. liver). Continuous functions could be derived for most system parameters describing a Caucasian population from 20 to 99 years with variability. Areas with sparse data have been identified like tissue composition, but knowledge gaps were filled with plausible, qualified assumptions. The developed population was implemented in Matlab® and estimated system parameters from 1,000 virtual individuals were in accordance to independent observed data showing the robustness of the developed population.

Conclusion
The developed repository for aging subjects provides a singular specific source for key system parameters needed for PBPK modelling and can in turn be used to investigate drug kinetics and DDI magnitudes in elderly.
2 Key Points

The developed repository provides a singular, specific source of age-dependent anatomical, physiological and biological system parameters required to inform physiologically based pharmacokinetic (PBPK) models. The parameters and associated developed equations can be implemented into existing PBPK frameworks and can be used to overcome sparse clinical data in aging subjects older than 65 years to investigate age-dependent changes in drug kinetics and drug-drug interaction (DDI) magnitudes in silico. These parameterized and informed PBPK models for elderly can provide more rational frameworks for dose-adjustments to overcome DDIs.
3 Introduction

In recent years the number of elderly people worldwide has increased substantially [1]. An “elderly” is defined as being above the age of 65 years [2], which is in line with the age of retirement in most Western countries. Older individuals are prone to multi-morbidities and hence polypharmacy and in turn for drug-drug interactions (DDIs) [3-5], however there is no clear pharmacological or clinical definition of “elderly” [6]. Often, elderly subjects are excluded from clinical trials resulting in a general lack of knowledge about the efficacy, safety and kinetics of a drug at different ages [7]. There are certain age-dependent anatomical, physiological and biochemical changes influencing drug kinetics including decreased kidney weight [8], reduced renal blood flow [9], reduced glomerular filtration rate (GFR) [10] and reduction in liver volume and blood flow [11-13]. For other parameters like enzyme and transporter abundance, or the concentration of plasma binding proteins, data are limited, contradictory or missing. In addition, it is difficult to investigate aging, because other environmental and behavioral factors like diseases, food and smoking can have effects themselves or enhance the aging process [14].

Physiologically based pharmacokinetic modelling can help to overcome the lack of clinical data and to understand drug absorption, distribution, metabolism and elimination at different ages. Furthermore, PBPK models predict DDI magnitudes in aging individuals and support more rational identification of dose adjustments to overcome DDIs. To develop a PBPK model, system data (where system refers to the population of interest – e.g. elderly) are required to inform the PBPK model. To generate reliable predictions, a comprehensive description of system characteristics is essential to fully represent the population of interest. To date only two databases have been published to inform PBPK models for elderly, of which one does not distinguish between ethnicities [15] and the other does not consider population variability and provides no descriptive functions of physiological and anatomical parameters [16].

The objective of this work was to collate and analyze data from the literature with the view to create a new comprehensive description of system characteristics for PBPK modelling and to address shortcomings of previous databases. The work focuses on parameters to inform a PBPK model for aging people that considers population variability, and to develop continuous functions describing physiological parameters of interest between 20 and 99 years of age for a Caucasian population.
4 Methods

4.1 Data source

A structured literature search was performed using the MEDLINE database for age-dependency of anatomical, physiological and biological parameters required to inform a PBPK model for aging subjects. Keywords used were “aging”, “elderly” or “geriatric” plus the parameter of interest (Supplement S-Table 1 and S-Figure 1 for the investigated compartments of a PBPK model). No restrictions were applied regarding the language or the publication year of the article. Abstracts were screened, and studies included if the study population were Caucasians, at least age has been reported in addition to the parameter of interest, and subjects were healthy or their disease / organ function was deemed unlikely to affect the parameter of interest like the effect of chronic liver disease on brain blood flow [17]. Studies performed with North Americans and Australians were considered if at least 80% of the study population were of European heritage. Studies including subjects over the age of 65 years should report at least a mean age in age decades. The reference list of chosen articles was manually screened to identify further references.

4.2 Data analysis

Data analysis was performed in Matlab® 2015b. The parameter of interest was analyzed in age decades. Data were converted to consistent units and a normal distribution was assumed for each parameter to make published data comparable. If a study reported median, minimum and maximum, data were converted to the arithmetic mean and standard deviation according to Hozo et al. [18] and if the interquartile range was given, the conversion was done according to Wan et al. [19].

Collated data were separated into a development and verification dataset. Studies in the development dataset were required to report age, sex, body height, body weight and the ethnicity in addition to the parameter of interest as necessary covariates to describe correlations. Otherwise, studies with less reported covariates were used in the verification dataset. If at least three different studies covering the entire age range with at least one value in each age decade and all required covariates for the development dataset were available for a parameter of interest, the data was randomly separated into a development and a verification dataset. In the case of missing covariates like anthropometric
parameters in the verification dataset or cardiac output for regional blood flow analysis, the covariates have been estimated by the derived equations following the approach by Williams & Leggett [20]. The body surface area was calculated according to DuBois & DuBois [21].

Weighted linear regression was performed to derive descriptive, continuous equations for the parameter of interest from 20 to 99 years considering age, sex, anthropometric parameters, location of the study, the publication year and methods of measurement as independent variables. Location was used as an independent variable to investigate if studies conducted in Europe, North America and Australia can be combined without bringing a bias into the data. Publication year has been used to investigate differences in key parameters (e.g. body weight) over the last century and if different methods used at different times have an impact. Data obtained by different methods have only been pooled when there was no significant difference between methods.

Linear, polynomial and exponential functions were investigated during regression analysis. Covariates with a p-value below 0.01 have been considered as significant. Visual and numerical regression diagnostic were performed. The corrected Aikake’s information criterion was used for numerical diagnostics to select the best fitted function [22]. Variability for each parameter was calculated as the weighted coefficient of variance (CV) of the development dataset for each individual mean and standard deviation and it was visually investigated whether age has an impact on variability. The variability of a parameter of interest is estimated by the variability of the covariates describing the parameter of interest and if necessary additional random variability to fully capture the observed variability.

The derived equations for all parameters necessary to describe a white population have been implemented in Matlab® and 1,000 virtual men and women have been created and the estimated system parameters have been compared to the independent verification dataset. Normal distribution with the derived CV (Tab. 1) was used to describe variability of the parameter of interest. Furthermore, it was analyzed if the sum of organ weights and regional blood flows do not exceed body weight and cardiac output.
5 Results

A total of 362 studies were found of which 318 studies were included in the analysis. Studies were mostly excluded because age or ethnicity of the study population were insufficiently defined. Rich data were found for anthropometric parameters, adipose, brain, heart, kidney and liver. Data for some regional blood flows, such as to the bone, and in general composition of tissues were difficult to obtain from the literature. Although including data for centenarians, most of the data were found for ages up to the mid-eighties identifying a general knowledge gap for the very old. Derived equations and the population variability expressed as the CV can be found in Table 1. Detailed information on the number of subjects in each age decade used in the development dataset (S-Table 2), the number of total studies in the development and verification dataset, the methods used to measure the parameter of interest, the study location and the references (S-Table 4) can be found for each investigated parameter in the supplement.

5.1 Age and sex distribution

Data regarding age and sex distribution were taken from Eurostat [23] for all 28 member states of the European Union and the Federal Office for Statistics of Switzerland [24] (Figure 1). The number of subjects in each age decade was found to be uniform between 20 and 59 years. The number of subjects declined from the age of 60 years, with only 2% of the Swiss population being above 90 years. A Weibull distribution with $\alpha = 1.55$ and $\beta = 61.73$ best described the age distribution. The proportion of women was found to be 50% of the population in Europe till the age of 69 years and increased to over 80% for very old Swiss subjects above the age of 100 years. In all following equations, age is expressed in years and sex is either 0 for men or 1 for women.

5.2 Body height and body weight

Anthropometric data of 106,698 Caucasians have been analyzed in the developmental dataset [24-70] and the derived equation has been verified with data from 14,096 subjects [71-86]. The mean body height of Caucasians aged 20 to 59 years was 178 cm for men and 166 cm for women with a gender-independent CV of 3.8%. Body height declined 2% per age decade from the age of 60 years (Figure 2). The difference between men and women was constant at all age ranges. Location was found to be a
significant variable during regression, with lower height observed in Southern Europe, and an exclusion of data reported from Portugal, Spain and Italy led to a non-significance of location.

The mean body weight of a Caucasian aged 20 to 49 years was 79.9 kg for men and 64.1 kg for women with a CV of 15.7% (Figure 2). Body weight increased in subjects in the 5th and 6th age decade about 4% and decreased afterwards about 10% in each age decade. In women, the decline started one age decade later than in men. In contrast to body height, location was not significant for body weight, but publication year was with a significant increase since 2000.

5.3 Liver

5.3.1 Liver weight
Liver is the major organ of metabolism. Liver weight was analyzed from over 3,000 subjects [29, 41, 51, 52, 55, 69, 72, 78, 87, 88] and was found to be on average 1.78 kg in men and 1.49 kg in women with a CV of 23.7% till the age of 65 years. Thereafter, liver weight decreased by 10 to 15% in women per age decade reaching 1.03 kg at the age of 100 years. The decrease in men was around 20% per age decade reaching 1.01 kg on average in 90 years old individuals (Figure 3).

5.3.2 Liver blood flow
Absolute total liver blood flow decreased by 60% between 60 and 90 years in men and women, but relative to cardiac output the changes were only significant between 90 and 100 years of age [13, 89]. The age-dependent changes in total liver blood flow might come from changes of the splanchnic blood flow [77, 89-94] explaining observed differences in the first pass effect between young and old subjects [95-97]. The hepatic arterial blood flow appears to be constant with age [20, 89, 98].

5.3.3 In-vitro-in-vivo extrapolation factors
PBPK models are informed by in-vitro-in-vivo extrapolation meaning that for instance the in vivo clearance is extrapolated from measured in vitro data. Hepatic scaling factors like the hepatocellularity (HPGL) or microsomal proteins per gram liver (MPPGL) are needed [99]. Barter et al. reported age-dependent equations for HPGL [100] and MPPGL [101] with the oldest individuals in the analysis being between the mid-seventies and the early eighties.
5.3.4 Hepatic enzyme activity

Studies concerning the age-dependency of hepatic CYP enzyme activity are sparse and contradictory. The biggest challenge is the high variability in hepatic CYP enzyme abundance [102, 103] and the small sample size generally used for analysis [104, 105]. In a recent large meta-analysis investigating hepatic CYP abundance to inform PBPK models, age was only a significant covariate for CYP2C9 [103]. It is worthwhile mentioning, that the different genotypes known for CYP2C9 increase the sample size needed to identify age-dependency even further. A significant age-dependency was detected for CYP1A2, CYP2D6 and CYP2E1 in a different study, but not for CYP2C9 [106]. In a third study, CYP1A2 activity was reported to be independent of age [107]. Consistent between different studies, CYP3A4 activity is reported to be independent of age [108-110].

Posalek et al. investigated drug clearances in elderly for probe substrates like caffeine (CYP1A2), warfarin (CYP2C9), phenytoin (CYP2C19), desipramine (CYP2D6) and midazolam (CYP3A4) and found a clearance decrease of 30 to 40% in 70 years old subjects compared to young individuals, which can be explained by the decline in liver volume and blood flow rather than hepatic CYP enzyme activity [111]. In addition inflammation affects CYP enzyme activity [112] making it difficult to analyze data from non-healthy elderly.

UGT enzyme activity is reported to be independent of age in the literature [106, 113-115]. Taken together, this lack of evidence and data to inform age dependency necessitates a more judicious approach to assume no age-dependent hepatic enzyme activity and thus assume the same values in aging subjects as in young individuals.

5.3.5 Hepatic drug transporter activity

Recently, a compact meta-analysis about hepatic drug transporter abundance to inform a PBPK model was published and age was tested as a covariate in the analysis and was reported to be not significant for any hepatic drug transporter [116]. In a PBPK model, we are interested in activity rather than abundance because the activity of enzymes and drug transporters can explain the observed data. If the abundance of transporter does not change, there might still be an age-dependent difference in transport
activity; however, these data are currently not available. Comparable to hepatic enzymes, it is therefore recommended to use the same activity in elderly as in young subjects.

5.4 Kidney

5.4.1 Kidney weight

The literature search yielded nine different studies with a total of 1,620 data points measuring kidney weight after autopsy [29, 41, 42, 51, 52, 55, 69, 78, 85] (Figure 4A). The average kidney weight in young males and females was 0.318 kg with a CV of 19.3% and 0.259 kg with a CV of 23.2%, respectively. The reduction in kidney weight increased with age starting from 5% at the age of 70 years to 15% at the age of 80 years to 25% up to the age of 100 years in both genders.

5.4.2 Kidney blood flow

Absolute kidney blood flow decreased by 5 to 10% per age decade till the age of 65 years and thereafter decreased by 25% per age decade (Figure 4B) [77, 90, 94, 117-125]. Kidney blood flow relative to cardiac output was 19.7% in young men and decreased to 11.9% at the age of 85 years. The decrease was 5 to 20% per age decade. In women, the average kidney blood flow relative to cardiac output was 16.5% and stayed constant till the age of 70 years. Thereafter, it decreased to 9.2% at the age of 85 years.

5.4.3 Glomerular filtration rate

Only studies using inulin or $^{51}$Cr-EDTA as a biomarker for glomerular filtration rate have been considered in this work [117-123, 125-129]. Equations to estimate the glomerular filtration rate like Cockcroft-Gault [10] and the modification of diet in renal disease [130] use serum creatinine, which is problematic considering senile sarcopenia in aging subjects [131]. The average glomerular filtration rate was between 130 – 140 mL/min in men aged between 20 and 50 years and around 120 mL/min in women of the same age. In the 5th age decade, glomerular filtration rate declined in men to 115 mL/min, which was like the value in women (112 mL/min). Afterwards, the decline in glomerular filtration rate was roughly 10% per age decade independent of gender reaching 50% of the value of a young adult at the age of 90 years (Figure 4C).
5.5 Adipose

5.5.1 Adipose weight

Adipose weight is usually measured via X-ray absorptiometry and bioelectric impedance analysis. Data from 18 different studies from 12,323 subjects were available for the development dataset [25, 26, 36, 37, 41, 42, 45-48, 57, 59, 60, 62, 65, 68, 73, 132]. In young men, adipose weight was on average 17.8 kg with a CV of 24%. It increased by 5 to 10% per age decade to 22.9 kg at the age of 70 years. The CV increased to 28%. In young women, adipose weight was found to be 17.3 kg with a CV of 29%. Between 20 and 70 years, adipose weight increased to 25.2 kg with a CV of 37% in women and decreased again to 21.9 kg with a CV of 37% at the age of 85 years.

5.5.2 Adipose blood flow

Adipose blood flow increased from 5% in young to 9% in aged males and from 8% in young to 10% in aged females [133, 134].

5.6 Muscle

5.6.1 Muscle weight

Data from 11 different studies with 5,542 participants were available to analyze muscle weight, which was measured by X-ray absorptiometry and bioelectrical impedance analysis [26, 41, 42, 45, 50, 64, 73, 79, 81, 83, 132]. The average muscle weight was 32.0 kg in men aged 20 to 65 years and 19.8 kg in women of the same age. Muscle weight decreased by 10% per age decade between 65 and 100 years. The CV was 11.8% and was similar for males and females.

5.6.2 Muscle blood flow

Only sparse data concerning muscle blood flow have been found in the literature which do not cover all age decades but suggesting 17.5% of cardiac output in men and 11.1% in women [135-138].
5.7 **Brain**

5.7.1 **Brain weight**

Brain weight was analyzed by using data from eight different studies with 2,425 participants [29, 41, 42, 51, 52, 55, 78, 139] and was found to be independent of age. The average brain weight was 1.39 kg in males and 1.28 kg in females with a gender-independent CV of 9%.

5.7.2 **Brain blood flow**

The literature search yielded 12 different studies with 956 participants for brain blood flow [140-151]. Brain blood flow relative to cardiac output was 11.8% in men and 15.6% in women below the age of 40 years and increased to 15.6% in men and 16.3% in women in the 4th age decade and was constant thereafter.

5.8 **Heart**

5.8.1 **Heart weight**

Heart weight was analyzed using data from 10 different studies measuring heart weight after autopsy [29, 41, 42, 53, 55, 61, 69, 78, 152, 153] and increased in both, males and females, from 0.325 kg and 0.241 kg at the age of 25 to 0.390 kg and 0.317 kg in the 9th age decade.

5.8.2 **Heart blood flow**

Blood flow to the heart relative to cardiac output increased from 5.5% at the age of 25 years to 12% at the age of 85 years in men and from 4.3% at the age of 25 years to 11.3% at the age of 70 years in women [154-159].

5.8.3 **Cardiac output**

Cardiac output is the volume of blood being ejected by the heart per minute. Data from 12 studies involving 645 subjects were used to analyze cardiac output [39, 63, 70, 74, 77, 84, 90, 94, 135, 138, 160, 161]. Cardiac output decreased from 352 L/h in 30 years old males and 312 L/h in young females between 5 and 10% every age decade to 258 L/h in aged males and 201 L/h in aged females (Figure 5). The CV was similar between both genders with a value of 21.1%.
5.9 Blood

5.9.1 Blood weight
Blood weight was analyzed from seven different studies with 382 male and 179 female participants [27, 30, 31, 44, 66, 75, 162]. In young males, blood weight was 5.8 kg with a CV of 10% and decreased to 5.0 kg at the age of 90 years (Figure 6). In young women, blood weight was lower with 3.8 kg, but stayed constant over different age decades. At the age of 70 years, female blood weight was still 3.7 kg. The CV was like in men.

5.9.2 Hematocrit
Blood parameters that have been analyzed were hematocrit and the concentration of albumin and alpha-acidic glycoprotein (Figure 6). Data of 1,752 subjects aged 21 till 90 years were available to analyze hematocrit [122, 142, 163-168]. Sex was the only significant covariate. Mean values were 0.443 ± 0.064 for men and 0.410 ± 0.063 for women.

5.9.3 Plasma binding protein concentration
Alpha-acidic glycoprotein showed no significant covariate when analyzing data of 472 subjects aged 24 to 90 years from five different studies [169-173]. The mean value was 0.798 g/L with a CV of 24.3%.

Regression analysis of albumin yielded age as a significant covariate [169, 174-181] with an overall CV of 7.9%. Albumin concentration declined about 1.5% in each age decade. Malnutrition and acute illnesses, occurring both often in the elderly, can have a significant impact on albumin concentration complication the analysis of age-dependent albumin concentration [172, 174, 179]. Therefore, only data from apparently healthy subjects have been used in the analysis.

5.10 Other organs
Other organs like spleen and pancreas are not described in detail here, but the descriptive equations to describe an aging Caucasian population can be found in Table 1 and more detailed information can be found in the Supplement (S-Table 2, 3 and 4).
5.11 Tissue composition

Tissue composition is an important parameter to predict the distribution of drugs into tissues in a PBPK model. Data regarding the composition of lipids and proteins of tissues are generally sparse in humans and no age-dependency was found in the literature, but total body water, total extracellular water and total body cell mass have been reported in aging subjects [26, 37, 65, 182-190]. Age-independent fraction of tissue volumes [191] coupled with age-dynamic tissue volumes have been used to calculate the vascular and interstitial space of tissues (representing the extracellular water) and the intracellular space minus the intracellular water (representing the cell mass). Organ densities to convert organ weight obtained from the derived functions to volumes have been used from the ICRP database [192, 193]. The weighted mean of the organ density and the fraction of tissue compositions of investigated organs was used for the remaining organ. The values of all tissues have been summed up and compared against the observed data (Figure 7). The prediction of total body water and total cell mass were well in agreement with the observed data leading to the conclusion that the made assumptions were adequate to inform a PBPK model.

5.12 Parameters affecting drug absorption

Physiological parameters having an impact on drug absorption are gastric pH, gastric emptying and small intestinal transit time, the surface area available for absorption, and intestinal enzyme and drug transporter abundance.

5.12.1 Gastric pH

One study compared gastric pH in fasted and fed state between 24 young, healthy volunteers aged 21 to 35 years [194] and 79 subjects aged 65 to 83 years [195]. The study reported a significant age-dependent difference between the median pH in fasted state (interquartile range) with 1.72 (1.08 – 2.34) in the young group and 1.28 (0.90 – 5.60) in the aged group. The variability appeared to be much greater in older individuals, but the difference in sample size need to be kept in mind. Another study in young subjects below the age of 65 years found a median fasted pH of 1.45 [196]. To conclude, it is doubtful if there is an age-dependency of gastric pH in fasted state and more data need to be generated and included in the meta-analysis to judge the age effect properly. Gastric pH in fed state was not significantly different between young and elderly subjects [194, 195], but the decline of gastric pH from
fed to fasted state was exponential with a half-life of 1.8 hours (CV: 65%) in young and was linear with
a half-life of 3.0 hours (CV: 80%) in aging subjects [195]. 8% of Caucasians are achlorhydric meaning
they do not secret hydrochloric acid in the gastric juice [197] and thus having a gastric pH at fasted state
of 7.1 [195]. In Japanese, the number of achlorhydric subjects increases with age [198], but this appears
not to be the case in healthy aging Caucasians [195].

5.12.2 Gastric emptying time

Reports in the literature about gastric emptying time are contradictory. Some studies report a slower
gastric emptying time [199, 200] in aging subjects, some report no changes [201, 202] and some a faster
rate [203, 204]. A lot of influencing factors exist for gastric emptying time like gastric pH [205], particle
size [203] and food [202, 203, 206] making it difficult to analyze age-dependency. Furthermore, gastric
emptying has a circadian rhythm making a difference if the study is conducted in the morning or in the
evening [207]. Two studies have investigated gastric emptying time after fluid and food intake in young
controls and aging subjects [206, 208]. Both studies used the same marker, the same method and both
started in the morning. Gastric emptying time was different between fluids and food but did not show
any age-dependency, which was verified by the regression analysis. Therefore, it is recommended to
use the same gastric emptying time in aging subjects as in young individuals.

5.12.3 Small intestinal transit time

Small intestinal transit time appears to be independent of age and a fixed value can be used to inform
a PBPK model [209, 210].

5.12.4 Passive permeability

The mucosal area is reported to decline with age [211, 212], but enterocytes and villi appear to be
unchanged [212]. Malnutrition, disease and drug intake could alter the mucosa and need to be carefully
considered when investigating age-dependency. Passive permeability was reported to be impaired in
aging subjects [211], but two studies investigating mannitol and lactulose, two carbohydrates which are
passively absorbed, showed no difference in passive permeability between young controls and aging
subjects after correcting the data for the age-dependent decline in glomerular filtration rate [213, 214].
It is therefore assumed that neither the surface area available for passive diffusion nor the rate of passive diffusion differ in aging subjects compared to young individuals.

5.12.5 **Intestinal enzyme and drug transporter abundance**

Data regarding intestinal enzyme and drug transporter abundance are generally sparse and therefore age-dependency cannot be analyzed sufficiently.
6 Discussion

The described population database for aging subjects summarizes anatomical, physiological and biological system parameters required to inform PBPK modelling. Descriptive, continuous functions for systems parameters from the age of 20 to 99 years have been derived and verified with observed data extracted from peer-reviewed literature. Population variability was considered for each parameter.

Two previous databases have been described in the literature for aging individuals. Thompson et al. gathered extensive data from the literature, but the authors did not consider different ethnic groups and combined data from Caucasians, Latin-Americans and Asians [15]. However, it is known that ethnicity can have a significant impact on system parameters, for instance hepatic enzyme abundance, and therefore on clearance prediction [215]. Schlender et al. published recently a database for elderly individuals further processing the data from Thompson et al. for Caucasians only [16]. A limitation of this study is that only values for organ weight and blood flow for each age decade were considered making it difficult to extrapolate to other ages of interest. Furthermore, population variability of system parameters was not considered by Schlender et al., which is an essential element for reasonable predictions of drug kinetics using PBPK models [216].

One notable novelty of the presented repository for Caucasian subjects are the derived continuous functions that allow prediction for a population from 20 to 99 years of age. The advantage of continuous functions is the creation of only one population with one distinct value at a certain age. If two separated populations would have been built with one representing young subjects from 20 to 65 years and one elderly individuals from 65 to 99 years, there would be two separated equations calculating system parameters at the age of 65 which might lead to un-physiological steps. Another advantage for the prediction of monoclonal antibody kinetics or long-term drug therapies could be to introduce time-varying physiology [217] so that subjects age during the time of the simulation.

A few limitations need to be acknowledged. Data from individuals over the age of 85 are sparse (S-Table 2 in the Supplement) meaning the derived equations could be less robust and extrapolation to older ages might be difficult. However, data for centenarians have been included for some system parameters [78] and were adequately estimated by the derived functions. Clinical studies are usually not performed in the very old making it impossible to verify the described population by analyzing drug
kinetics. It is therefore recommended to use the described repository with caution at older ages. This
holds particularly true for regional blood flows to adipose, heart, muscle and skin, because almost no
geriatric data are currently available in the literature.

Another area with sparse data, where more research is needed in the future, is tissue composition being
important to predict the distribution into tissues accurately. It was shown that the assumptions used in
this work are plausible for total body water and cell mass (Figure 7), however, exception for single
tissues cannot be excluded and data for lipid composition in the elderly were generally not found in the
literature.

The analysis of system parameters to inform a PBPK model for aging Caucasians was complicated by
the fact that some studies combine age groups together, meaning individuals aged 65 to 100 years
might have been included, but only a mean age is given. This can lead to a bias in the data and hinders
the characterization of age-dependent changes. Reports that insufficiently described age should
generally be excluded unless no other data are available. Furthermore, ethnicity, particular in European
studies, is not always clearly defined and need to be assumed from the given study location.

Predictions of system parameters become more robust when model parameters are correlated with
each other and covariability can be described [218, 219]. To obtain such descriptive correlations, studies
need to report important covariates, which is unfortunately not always the case. Weighted regression
analysis has been used to correlate parameters and to receive a more robust aging population. Linear
regression can only describe linear relationships, however, using data transformation such as logarithm
might compensate. Using regression, it is easy to overfit and model the noise in the data rather than the
relationship between parameters. In this work, the corrected Akaike's information criterion was used to
select the best performing function among the tested ones, which in contrast to the coefficient of
determination exhibits no bias to higher parameterized models. Another limitation of regression analysis
is its sensitivity towards outliers. Visual inspection of the estimated mean and variability of each
parameter compared to observed data in this work, did show an adequate fit all investigated parameters
(Figure 2 to 7).
The evaluation of variability was further complicated by being unable to set boundaries for publication year and study location. For a few parameters, for instance blood weight, data were only available from specific regions (e.g. United States) and from the 1950s. Both, location and publication year have therefore been used as independent variables during regression and their impact has been quantified when sufficient data were available. Body height and body weight are key parameters to describe a population adequately and data from 106,698 individuals were available. Location was found to have an impact to body height, with lower height correlated with Southern Europe. Otherwise, location was not a significant covariate for any variable and therefore combining data of studies conducted in Europe, the United States and Australia appears not to bring a bias into the data. However, the derived equations should not be used to predict aging Africans or Asians as aging processes might be different. Publication year had a significant impact on body weight showing the weight increase particularly in the last ten years. Consequently, the developed population will require constant updates to include future potential changes like body weight.

A challenge when studying older individuals is that the definition of elderly is not universal. The WHO specifies elderly as being above the age of 65 years [2], which is in accordance with the age of retirement in most Western countries, but a clear pharmacological or clinical age-cut off is missing [6]. For some patient groups, like people infected with HIV, the age cut-off is even as early as 50 years [220]. We compared organs parameters important for drug disposition for 50 and 70 years old men and women with 30 years old subjects (Figure 8). There is a progressive decline in relevant system parameters, such as adipose weight, liver and kidney blood flow, with age. However, it is challenging to conclude a “pharmacological” or “clinical” age cut-off for elderly based on the age-dependent changes in anatomical and physiological parameters, because it is unknown when those changes affect drug kinetics significantly. No study has been undertaken to compare pharmacokinetics of a drug between different age decades and correlate those data to age-dependent changes of organ parameters. Furthermore, elderly subjects included in clinical trials can have diseases influencing the parameter of interest. It is therefore a challenge to define “healthy” in terms of an aged person.

Despite the limitations, in this work it was possible to derive descriptive, continuous functions to generate a virtual population from 20 to 99 years in accordance to observed, independent data. Elderly are a growing vulnerable patient population with a high frequency of co-morbidities and in turn polypharmacy.
However, aging subjects are often excluded from clinical trials and knowledge concerning drug kinetics and DDI magnitudes are scarce. The developed population database can be implemented into existing PBPK frameworks and can in turn be used to predict drug kinetics and DDI magnitudes in aging subjects overcoming the lack of clinical data and providing a rational framework for dose optimization to overcome DDIs.
7 Conclusions

The population database for aging subjects presented in this work can be implemented into existing PBPK frameworks and allows the prediction of drug kinetics and DDI magnitudes in elderly. It provides descriptive, continuous functions for anatomical and physiological parameters from 20 to 99 years necessary to inform PBPK models and provides a view of the current literature concerning metabolizing enzymes and drug transporters in aging individuals. Furthermore, population variability is considered for all system parameters providing a framework for realistic pharmacokinetic predictions.
8 Funding.

This study was supported by the Swiss National Foundation (Grant number 166204), the OPO Foundation and the Isaac Dreyfus Foundation.

9 Conflict of Interest

Felix Stader, Marco Siccardi, Manuel Battegay, Hannah Kinvig, Melissa A. Penny, and Catia Marzolini have no conflict of interest to declare.
References


61. Smith HL. The relation of the weight of the heart to the weight of the body and of the weight of the heart to age. American Heart Journal. 1928;4(1):79-93.


Gastric emptying and small intestinal transit times.


11 Figures

Figure 1: Proportion of subjects (1A) and proportion of women (1B) per age decade. Data are from the 28-member states of the European Union (black bars) and Switzerland (white bars).

Figure 2: Body height (2A) and body weight (2B) per age decade in an aging population. The blue, red and black lines represent the predicted mean of virtual males, virtual females and from all virtual subjects, respectively. The dashed lines represent the 5 and 95% percentile of the predictions. Stars show observed data from the development and circles represent overserved data from the independent verification dataset. The size of the stars and circles indicates the size of the studied population.
Figure 3: Liver weight (3A) and liver blood flow (3B) per age decade in an aging population. The blue, red and black lines represent the predicted mean of virtual males, virtual females and from all virtual subjects, respectively. The dashed lines represent the 5 and 95% percentile of the predictions. Stars show observed data from the development and circles represent observed data from the independent verification dataset. Black circles represent data from an undefined gender population. The size of the stars and circles indicates the size of the studied population.

Figure 4: Kidney weight (4A), kidney blood flow (4B) and glomerular filtration rate (4C) per age decade in an aging population. The blue, red and black lines represent the predicted mean of virtual males, virtual females and from all virtual subjects, respectively. The dashed lines represent the 5 and 95% percentile of the predictions. Stars show observed data from the development and circles represent observed data from the independent verification dataset. Black circles represent data from an undefined gender population. The size of the stars and circles indicates the size of the studied population.
Figure 5: Cardiac output per age decade in an aging population. The blue, red and black lines represent the predicted mean of virtual males, virtual females and from all virtual subjects, respectively. The dashed lines represent the 5 and 95% percentile of the predictions. Stars show observed data from the development and circles represent observed data from the independent verification dataset. The size of the stars and circles indicates the size of the studied population.

Figure 6: Blood weight (6A), hematocrit (6B), albumin (6C) and alpha-acid glycoprotein (6D) concentration per age decade in an aging population. The blue, red and black lines represent the predicted mean of virtual males, virtual females and from all virtual subjects, respectively. The dashed lines represent the 5 and 95% percentile of the predictions. Stars show observed data from the development and circles represent overserved data from the independent verification dataset. Black circles represent data from an undefined gender population. The size of the stars and circles indicates the size of the studied population.
Figure 7: Total body water (7A) and total body cell mass (7B) per age decade in an aging population. The blue, red and black lines represent the predicted mean of virtual males, virtual females and from all virtual subjects, respectively. The dashed lines represent the 5 and 95% percentile of the predictions. Stars show observed data from the development and circles represent observed data from the independent verification dataset. The size of the stars and circles indicates the size of the studied population.
Figure 8: Comparison of a 50 and 70 years old man (8A and 8B) and women (8C and 8D) with a 30 years old subject, who was arbitrarily chosen to represent a young individual. Blood flow is relative to cardiac output and all values are relative to a 30 years old man and women, respectively.
### Tables

Table 1: Descriptive equations and population variability for anatomical, physiological and biological parameters necessary to inform a PBPK model. Virtual subjects from 20 to 99 years can be generated. Blood flows are relative to cardiac output and the variability is only propagated from cardiac output. \( m \) indicates male and \( f \) female, when there was a gender-related difference in the CV.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Unit</th>
<th>Descriptive equation</th>
<th>CV [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body height</td>
<td>cm</td>
<td>(-0.0039 \times Age^2 + 0.238 \times Age - 12.5 \times Sex + 176)</td>
<td>3.8</td>
</tr>
<tr>
<td>Body weight</td>
<td>kg</td>
<td>(-0.0039 \times Age^2 + 1.12 \times Body height + 0.611 \times Age - 0.424 \times Sex - 137)</td>
<td>15.2</td>
</tr>
<tr>
<td>Lung weight</td>
<td>kg</td>
<td>(e^{(0.028 \times \text{Body height} + 0.0077 \times \text{Age} - 5.6)})</td>
<td>0</td>
</tr>
<tr>
<td>Adipose weight</td>
<td>kg</td>
<td>(0.68 \times \text{Body weight} - 0.56 \times \text{Body height} + 6.1 \times \text{Age} + 65)</td>
<td>29.6</td>
</tr>
<tr>
<td>Bone weight</td>
<td>kg</td>
<td>(e^{(0.024 \times \text{Body height} - 1.9)})</td>
<td>13.2</td>
</tr>
<tr>
<td>Brain weight</td>
<td>kg</td>
<td>(e^{-0.0075 \times \text{Age} + 0.78 \times \text{Body height} - 0.97})</td>
<td>9.0</td>
</tr>
<tr>
<td>Gonad weight</td>
<td>kg</td>
<td>(-0.00034 \times \text{Body weight} - 0.00022 \times \text{Age} - 0.03 \times \text{Sex} + 0.072)</td>
<td>34.8</td>
</tr>
<tr>
<td>Heart weight</td>
<td>kg</td>
<td>(0.34 \times \text{BSA} + 0.0018 \times \text{Age} - 0.36)</td>
<td>17.9 (m), 22.7 (f)</td>
</tr>
<tr>
<td>Kidney weight</td>
<td>kg</td>
<td>(-0.00038 \times \text{Age} - 0.056 \times \text{Sex} + 0.33)</td>
<td>19.3 (m), 23.2 (f)</td>
</tr>
<tr>
<td>Muscle weight</td>
<td>kg</td>
<td>(17.9 \times \text{BSA} - 0.0667 \times \text{Age} - 5.68 \times \text{Sex} - 1.22)</td>
<td>11.8</td>
</tr>
<tr>
<td>Skin weight</td>
<td>kg</td>
<td>(e^{(-0.0058 \times \text{Age} - 0.37 \times \text{Sex} + 1.13)})</td>
<td>8.3</td>
</tr>
<tr>
<td>Thymus weight</td>
<td>kg</td>
<td>0.0221</td>
<td>44.8</td>
</tr>
<tr>
<td>Gut weight</td>
<td>kg</td>
<td>(3 \times 10^{-6} \times \text{Body height}^{2.49})</td>
<td>7.3</td>
</tr>
<tr>
<td>Spleen weight</td>
<td>kg</td>
<td>(e^{1.13 \times \text{BSA} - 3.93})</td>
<td>51.7</td>
</tr>
<tr>
<td>Pancreas weight</td>
<td>kg</td>
<td>0.103</td>
<td>27.8</td>
</tr>
<tr>
<td>Liver weight</td>
<td>kg</td>
<td>(e^{(0.87 \times \text{BSA} - 0.0014 \times \text{Age} - 1)})</td>
<td>23.7</td>
</tr>
<tr>
<td>Blood weight</td>
<td>kg</td>
<td>(e^{(0.067 \times \text{BSA} - 0.0025 \times \text{Age} - 0.38 \times \text{Sex} + 1.7)})</td>
<td>10.4</td>
</tr>
<tr>
<td>Cardiac output (CO)</td>
<td>L/h</td>
<td>(159 \times \text{BSA} - 1.56 \times \text{Age} + 114)</td>
<td>21.1</td>
</tr>
<tr>
<td>Adipose blood flow</td>
<td>% of CO</td>
<td>((0.044 + 0.027 \times \text{Sex}) \times \text{Age} + 2.4 \times \text{Sex} + 3.9)</td>
<td></td>
</tr>
<tr>
<td>Bone blood flow</td>
<td>% of CO</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Brain blood flow</td>
<td>% of CO</td>
<td>(e^{-0.48 \times \text{BSA} + 0.04 \times \text{Sex} + 3.5})</td>
<td></td>
</tr>
<tr>
<td>Gonad blood flow</td>
<td>% of CO</td>
<td>(-0.03 \times \text{Sex} + 0.05)</td>
<td></td>
</tr>
<tr>
<td>Heart blood flow</td>
<td>% of CO</td>
<td>(-0.72 \times \text{Body height} - 10 \times \text{Sex} + 134)</td>
<td></td>
</tr>
<tr>
<td>Kidney blood flow</td>
<td>% of CO</td>
<td>(-8.7 \times \text{BSA} + 0.29 \times \text{Body height} - 0.081 \times \text{Age} - 13)</td>
<td></td>
</tr>
<tr>
<td>Muscle blood flow</td>
<td>% of CO</td>
<td>(-6.4 \times \text{Sex} + 17.5)</td>
<td></td>
</tr>
<tr>
<td>Skin blood flow</td>
<td>% of CO</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Thymus blood flow</td>
<td>% of CO</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Gut blood flow</td>
<td>% of CO</td>
<td>(2 \times \text{Sex} + 14)</td>
<td></td>
</tr>
<tr>
<td>Parameter</td>
<td>Unit</td>
<td>Descriptive equation</td>
<td>CV [%]</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------</td>
<td>-----------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Spleen blood flow</td>
<td>% of CO</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Pancreas blood flow</td>
<td>% of CO</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Liver blood flow</td>
<td>% of CO</td>
<td>$-0.108 \times Age + 1.04 \times Sex + 27.9$</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>g/L</td>
<td>$-0.0709 \times Age + 47.7$</td>
<td>7.9</td>
</tr>
<tr>
<td>GFR</td>
<td>mL/min</td>
<td>$e^{-0.0079 \times Age + 0.5 \times BSA + 4.2}$</td>
<td>14.7</td>
</tr>
</tbody>
</table>